PDF(Pubmed)
Abstract：
UNASSIGNED: This pilot study aimed to assess the feasibility, accuracy, and repeatability of unsupervised, at-home, multi-day glaucoma testing using the Olleyes VisuALL Virtual Reality Platform (VRP) and the iCare HOME handheld self-tonometer.
UNASSIGNED: Participants were trained to use two U.S. Food and Drug Administration-registered or approved devices before conducting self-tests at home over 3 consecutive days. The iCare HOME intraocular pressure (IOP) measurements were collected four times daily per eye, and VRP visual field tests were performed once daily. The results were compared with one in-clinic Humphrey Field Analyzer (HFA) visual field test performed on the day of device training, iCare HOME measurements by the trainer, and the last five Goldmann applanation tonometer (GAT) results.
UNASSIGNED: Of 15 enrolled participants, nine of them (60%) completed the study. The six excluded participants could not self-measure using iCare HOME. There was significant correlation between the average mean deviation (MD) values of the at-home VRP tests and in-clinic HFA test (r2 = 0.8793, P < 0.001). Additionally, the average of the sensitivities in five of six Garway-Heath sectors were significantly correlated. VRP test duration was also shorter than in-clinic HFA testing (P < 0.001). Finally, at-home tonometry yielded statistically similar values compared to trainer-obtained iCare HOME values. The mean and range of at-home tonometry were also statistically similar to those for in-clinic GAT, but at-home tonometry demonstrated higher maximum IOP values (P = 0.0429).
UNASSIGNED: Unsupervised, at-home, multi-day glaucoma testing using two devices resulted in the capture of higher maximum IOPs than in the clinic and good MD correlation of VRP with HFA. However, 40% of participants could not self-measure IOP using iCare HOME.
UNASSIGNED: The study findings suggest that at-home remote glaucoma monitoring correlates with in-office testing and could provide additional information for glaucoma management, although patients had more difficulty with the iCare HOME than the VRP.
UNASSIGNED: Participants were trained to use two U.S. Food and Drug Administration-registered or approved devices before conducting self-tests at home over 3 consecutive days. The iCare HOME intraocular pressure (IOP) measurements were collected four times daily per eye, and VRP visual field tests were performed once daily. The results were compared with one in-clinic Humphrey Field Analyzer (HFA) visual field test performed on the day of device training, iCare HOME measurements by the trainer, and the last five Goldmann applanation tonometer (GAT) results.
UNASSIGNED: Of 15 enrolled participants, nine of them (60%) completed the study. The six excluded participants could not self-measure using iCare HOME. There was significant correlation between the average mean deviation (MD) values of the at-home VRP tests and in-clinic HFA test (r2 = 0.8793, P < 0.001). Additionally, the average of the sensitivities in five of six Garway-Heath sectors were significantly correlated. VRP test duration was also shorter than in-clinic HFA testing (P < 0.001). Finally, at-home tonometry yielded statistically similar values compared to trainer-obtained iCare HOME values. The mean and range of at-home tonometry were also statistically similar to those for in-clinic GAT, but at-home tonometry demonstrated higher maximum IOP values (P = 0.0429).
UNASSIGNED: Unsupervised, at-home, multi-day glaucoma testing using two devices resulted in the capture of higher maximum IOPs than in the clinic and good MD correlation of VRP with HFA. However, 40% of participants could not self-measure IOP using iCare HOME.
UNASSIGNED: The study findings suggest that at-home remote glaucoma monitoring correlates with in-office testing and could provide additional information for glaucoma management, although patients had more difficulty with the iCare HOME than the VRP.
摘要：
■这项试点研究旨在评估可行性，准确度,和无监督的可重复性，在家,使用OlleyesVisuALL虚拟现实平台（VRP）和iCareHOME手持式自眼压计进行多日青光眼测试。
■参与者在连续3天在家进行自我测试之前，接受了使用两种美国食品和药物管理局注册或批准的设备的培训。每只眼睛每天收集四次iCareHOME眼内压（IOP）测量值，和VRP视野测试每天进行一次。将结果与器械培训当天进行的一项临床Humphrey现场分析仪（HFA）视野测试进行比较，由培训师进行的iCareHOME测量，以及最后五个Goldmann压平眼压计（GAT）结果。
■在15名注册参与者中，其中9人(60%)完成了这项研究。六名被排除的参与者无法使用iCareHOME进行自我测量。家庭VRP测试和临床HFA测试的平均平均偏差（MD）值之间存在显着相关性（r2=0.8793，P<0.001）。此外,六个Garway-Heath部门中的五个部门的敏感性平均值显着相关。VRP测试持续时间也短于临床HFA测试(P<0.001)。最后,与培训师获得的iCareHOME值相比，在家中进行眼压测量产生了统计学上相似的值。在家眼压测量的平均值和范围也与临床GAT的平均值和范围在统计学上相似，但在家眼压测量显示出更高的最大眼压值(P=0.0429)。
■无人监督，在家,使用两种设备进行的多日青光眼测试导致捕获的最大IOP高于临床，并且VRP与HFA的MD相关性良好。然而,40%的参与者无法使用iCareHOME自我测量眼压。
研究结果表明，家庭远程青光眼监测与办公室检测相关，可以为青光眼管理提供更多信息，尽管患者使用iCareHOME比VRP更困难。
■参与者在连续3天在家进行自我测试之前，接受了使用两种美国食品和药物管理局注册或批准的设备的培训。每只眼睛每天收集四次iCareHOME眼内压（IOP）测量值，和VRP视野测试每天进行一次。将结果与器械培训当天进行的一项临床Humphrey现场分析仪（HFA）视野测试进行比较，由培训师进行的iCareHOME测量，以及最后五个Goldmann压平眼压计（GAT）结果。
■在15名注册参与者中，其中9人(60%)完成了这项研究。六名被排除的参与者无法使用iCareHOME进行自我测量。家庭VRP测试和临床HFA测试的平均平均偏差（MD）值之间存在显着相关性（r2=0.8793，P<0.001）。此外,六个Garway-Heath部门中的五个部门的敏感性平均值显着相关。VRP测试持续时间也短于临床HFA测试(P<0.001)。最后,与培训师获得的iCareHOME值相比，在家中进行眼压测量产生了统计学上相似的值。在家眼压测量的平均值和范围也与临床GAT的平均值和范围在统计学上相似，但在家眼压测量显示出更高的最大眼压值(P=0.0429)。
■无人监督，在家,使用两种设备进行的多日青光眼测试导致捕获的最大IOP高于临床，并且VRP与HFA的MD相关性良好。然而,40%的参与者无法使用iCareHOME自我测量眼压。
研究结果表明，家庭远程青光眼监测与办公室检测相关，可以为青光眼管理提供更多信息，尽管患者使用iCareHOME比VRP更困难。
